EC approves Spinraza, Brineura

The European Commission approved a pair of new drugs for rare diseases: Spinraza nusinersen from Biogen Inc. (NASDAQ:BIIB)

Read the full 180 word article

How to gain access

Continue reading with a
two-week free trial.